Next generation adoptive immunotherapy--human T cells as carriers of therapeutic nanoparticles.
An important step in adoptive immunotherapy in general and specifically with respect to cancer treatment is the initiation of an inflammatory T cell response at the tumor site. Here we suggest a new concept for a controlled inflammatory response in which the intrinsic cytotoxic properties of T cells are upgraded with the properties of nanoparticles transfected into the T cells during the ex vivo expansion process. We report in vitro upgrading of human T cells using PEGylated boron carbide nanoparticles functionalised with a translocation peptide aimed at Boron Neutron Capture Therapy (BNCT). A key finding is that the metabolism of such upgraded human T cells were not affected by a payload of 0.13 pg boron per cell and that the nanoparticles were retained in the cell population after several cell divisions. This is vital for transporting nanoparticles by T cells to the tumor site.
Mortensen
M W
MW
Nano-Science Center, University of Copenhagen, Universitetsparken 5, DK-2100 Copenhagen, Denmark.
Kahns
L
L
Hansen
T
T
Sorensen
P G
PG
Björkdahl
O
O
Jensen
M R
MR
Gundersen
H J G
HJ
Bjørnholm
T
T
D000595:Amino Acid Sequence; D004337:Drug Carriers; D005434:Flow Cytometry; D006801:Humans; D016219:Immunotherapy, Adoptive; D008969:Molecular Sequence Data; D053758:Nanoparticles / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology*
D004337:Drug Carriers